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Abstract
BACKGROUND
Indole-3-carbinol (I3C) and other aryl hydrocarbon receptor agonists are known
to modulate the immune system and ameliorate various inflammatory and
autoimmune diseases in animal models, including colitis induced by dextran
sulfate sodium (DSS). MicroRNAs (miRNAs) are also gaining traction as potential
therapeutic agents or diagnostic elements. Enterohepatic Helicobacter (EHH)
species are associated with an increased risk of inflammatory bowel disease, but
little is known about how these species affect the immune system or response to
treatment.
AIM
To determine whether infection with an EHH species alters the response to I3C
and how the immune and miRNA responses of an EHH species compare with
responses to DSS and inflammatory bowel disease.
METHODS
We infected C57BL/6 mice with Helicobacter muridarum (H. muridarum), with and
without DSS and I3C treatment. Pathological responses were evaluated by
histological examination, symptom scores, and cytokine responses. MiRNAs
analysis was performed on mesenteric lymph nodes to further evaluate the
regional immune response.
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RESULTS
H. muridarum infection alone caused colonic inflammation and upregulated
proinflammatory, macrophage-associated cytokines in the colon similar to
changes seen in DSS-treated mice. Further upregulation occurred upon treatment
with DSS. H. muridarum infection caused broad changes in mesenteric lymph node
miRNA expression, but colitis-associated miRNAs were regulated similarly in H.
muridarum-infected and uninfected, DSS-treated mice. In spite of causing colitis
exacerbation, H. muridarum infection did not prevent disease amelioration by I3C.
I3C normalized both macrophage- and T cell-associated cytokines.
CONCLUSION
Thus, I3C may be useful for inflammatory bowel disease patients regardless of
EHH infection. The miRNA changes associated with I3C treatment are likely the
result of, rather than the cause of immune response changes.
Key words: Helicobacter muridarum; MicroRNA; Immune; T regulatory cell; T helper 17
cell; Colitis; Cytokine
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The immune response to Helicobacter muridarum (H. muridarum), an
enterohepatic Helicobacter species, mimics responses seen during chemically induced
colitis and human inflammatory bowel disease (IBD) in terms of local and systemic
cytokine responses and microRNA changes. Most microRNAs that are altered in IBD are
also altered by H. muridarum infection with or without dextran sodium sulfate treatment.
Furthermore, H. muridarum does not alter activity of an aryl hydrocarbon receptor agonist,
indole-3-carbinol, a natural compound being explored as a treatment for IBD. Therefore,
H. muridarum infection provides a viable model for predicting the effects of enterohepatic
Helicobacter species on IBD.
Citation: Alkarkoushi RR, Hui Y, Tavakoli AS, Singh U, Nagarkatti P, Nagarkatti M,
Chatzistamou I, Bam M, Testerman TL. Immune and microRNA responses to Helicobacter
muridarum infection and indole-3-carbinol during colitis. World J Gastroenterol 2020; 26(32):
4763-4785
URL: https://www.wjgnet.com/1007-9327/full/v26/i32/4763.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i32.4763

INTRODUCTION
Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease (IBD)
characterized by inflammation of the colon. In the past decade, inflammatory bowel
disease has emerged as a public health challenge and a global disease with increasing
incidence in newly industrialized and industrialized countries worldwide, especially
in North America, and Europe[1]. In 2015, 3.1 million adults in the United States were
living with IBD[2], with direct and indirect costs estimated to be between $14.6 and
$31.6 billion in 2014 alone[3]. The pathogenesis of IBD is complex and influenced by
genetic susceptibility, dysregulation of the innate and adaptive immune systems,
environmental factors, and intestinal dysbiosis; however, a crucial feature of UC is the
imbalance between T regulatory (Treg) cells and T helper 17 (Th17) cells[4].
The best-known member of the Helicobacter genus is Helicobacter pylori (H. pylori),
which colonizes the stomach, causing gastritis, gastric cancer, and a range of
extragastric diseases[5]. Enterohepatic Helicobacter (EHH) species colonize the colon and
sometimes the biliary tree. Some of these poorly studied organisms commonly cause
persistent, asymptomatic infections, but occasionally cause intestinal diseases or even
cancer in species ranging from rodents to primates[6-8]. Several studies suggest that
EHH species are associated with IBD in humans[9-11]. The prevalence of EHH species in
human populations is not clearly known, but one study found 9% infection in healthy
control patients[11]. Helicobacter muridarum (H. muridarum) is an enterohepatic
Helicobacter (EHH) species that was initially described as a member of the normal flora
of conventional rodents[12]. Subsequent studies, however, showed that H. muridarum
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could induce colitis and gastritis in mice, suggesting a potential pathogenic role for the
bacterium[13-15].
Dextran sodium sulfate (DSS)-induced colitis is the most widely used mouse colitis
model for studying acute colitis and inflammation-associated colon cancer. DSS is a
water-soluble, negatively charged, sulfated polysaccharide with a highly variable
molecular weight. DSS-induced murine colitis, which most closely resembles human
UC, employs DSS at a molecular weight of 40000 Da[16,17]. The mechanism by which
DSS induces intestinal inflammation is disruption of tight junctions, allowing
dissemination of proinflammatory intestinal contents[18]. In conjunction with colonic
damage, DSS induces a range of proinflammatory cytokines and a Th1/Th17
response[17,19].
The aryl hydrocarbon receptor (AhR) regulates several signaling pathways relevant
to intestinal health, including the balance between Tregs and Th17 cells[20,21]. AhR is
needed for the survival of intraepithelial lymphocytes and also the organogenesis of
lymphoid structures in the gastrointestinal tract[22]. Indole-3-carbinol (I3C), a dietary
compound from cruciferous vegetables such as broccoli, activates AhR, as does its
acidic condensation product, 3,3’-diindolylmethane (DIM)[23]. Both I3C and DIM have
been investigated as treatments for a range of inflammatory diseases and cancers,
including colitis[24-26], but the effects of Helicobacter infection on the response to I3C has
not been studied. I3C and DIM are available for purchase as dietary supplements.
MicroRNAs (miRNAs) are being investigated as potential diagnostic and treatment
tools. MiRNAs are highly conserved, noncoding, single-stranded, small ribonucleic
acid molecules (17–27 nucleotides) that control gene expression post-transcriptionally.
They typically bind at the 3’ untranslated region of the target gene messenger RNA
(mRNA) leading to the degradation of the target RNA or inhibition of the translation
of the RNA[27,28]. MiRNAs regulate genes involved in a wide range of cellular signaling
pathways, including the Immune response. During the past ten years, much research
has been done to uncover their roles in cellular proliferation, differentiation,
maturation, and apoptosis[27]. Moreover, substantial scientific evidence underlines the
functional roles and potential value of these tiny ribonucleic acid molecules for
regulating autoimmunity and inflammation by affecting the differentiation,
maturation, and functions of various immune cells in diseases including colitis[28,29].
Furthermore, many pieces of evidence show the participation of miRNAs in the
regulation of T-cell development, differentiation, maturation, and activation[30]. Since
the Treg/Th17 balance is crucial to intestinal health[31], understanding how miRNA
expression is controlled by inflammatory and anti-inflammatory signals, such as I3C,
could lead to identification of miRNAs capable of rebalancing the immune response in
the inflamed colon.
The aims of this study were to examine the relative effects of H. muridarum and I3C
on mouse colon pathology, immune response, and miRNA expression. We used the
standard mouse model of DSS-induced colitis in C57BL/6 mice. Some groups were
infected with H. muridarum and treated with I3C. Treatment responses were monitored
in the colon and mesenteric lymph nodes.

MATERIALS AND METHODS
Animals
The research described in this manuscript (including the acquisition of animals and all
protocols for their use) was approved by the University of South Carolina Institutional
Animal Care and Use Committee prior to commencement of studies. University of
South Carolina is an AALAC accredited institution and all animal care procedures
followed the NIH Guide for the Care and Use of Laboratory Animals. Female
C57BL/6J mice (aged 8-10 wk) were purchased from The Jackson Laboratory, Bar
Harbor, Maine, United States. Animals were housed in a controlled environment (12 h
light/dark cycle) with food and water ad libitum. After one week of acclimation on a
normal chow diet, the mice were randomly divided into groups. Groups of 5-7 animals
were used in each experiment. The experimental groups included control (Ctrl), H.
muridarum, H. muridarum plus DSS, H. muridarum plus DSS plus I3C, DSS, and DSS
plus I3C (DSS/I3C). Each experiment included either all male or all female mice, as
indicated in the text.

Bacterial strains, cultivation, and infection
H. muridarum strain ATCC4982 was purchased from the American Type Culture
Collection and was cultured in a humidified environment at 37 °C with 10% CO2, 5%
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O2 in Ham’s F-12 medium containing 20 mL/L fetal calf serum in tissue culture flasks.
H. muridarum bacteria were passaged every 2 to 3 d. After microscopically verifying
appropriate morphology and motility, the culture was centrifuged at 25°C at 4500 rpm
for 20 min, then the pellet was suspended in 9 g/L sodium chloride to produce a
suspension containing approximately 28465 to 142072 adenosine triphosphate (ATP)
relative luminescence units per 200 μL, as determined using the luminescent BacTiterGlo ATP viability assay (Promega Corp.,Madison, Wisconsin, United States). Mice
were inoculated by orogastric gavage (200 µL) every other day for a total of four
inoculations. Viability of the remaining bacterial suspension was reconfirmed using
the luminescent BacTiter-Glo ATP assay.
Infection was confirmed by polymerase chain reaction (PCR) of stool DNA using H.
muridarum-specific primers as follows. Fecal samples were collected and stored at 80°C until analysis. Fecal DNA was isolated using the EZNA stool DNA kit (Omega
Bio-Tek, Inc., Norcross Georgia, United States) according to the manufacturer’s
recommendations. Fecal PCR was performed using H. muridarum 16S rRNA genespecific primers (H. m. p30f, 5’-ATGGGTAAGAAAAAAAAAGATTGCAA-3’, and H.
m. p30r, 5’-CTATTTCATATCCGCTCTTGAGAATC-3’), which amplify an 800 bp
conserved region of the 16S rRNA, as previously described[32].

Induction of colitis with DSS
DSS (MW 40 000, Chem-Impex International, Inc, Wood Dale, Illinois, United States) at
a concentration of 1-30 g/L was provided in drinking water for 10-13 d. The volume of
DSS consumed, animal weight, diarrhea score, and stool blood score were recorded
daily. The disease activity index was calculated from weight, diarrhea, and stool blood
scores as previously described[33,34]. Stool blood was detected using a colorimetric fecal
occult blood test (Helena Laboratories, ColoScreen catalog No. 5083). Briefly, we
determined the disease activity index using the following variables: Stool blood (0,
negative; 1, weakly positive; 2, strongly positive; 3, rusty-colored stool and 4, gross
bleeding), changes in weight (0, < 1%; 1, 1%-5%; 2, 6%-10%; 3, 11%-15%; and 4, > 15%),
and stool consistency (0-1, normal; 2-3, loose stools; and 4, diarrhea).

I3C preparation and dosage
For treatment groups, I3C purchased from Chem-Impex International, Inc. was
suspended in DMSO prior to dilution in corn oil. I3C was administered orogastrically
at a dose of 40 mg/kg in a total volume of 100 µL, as described previously[24]. Animals
were treated with either I3C or vehicle (20 mL/L DMSO in corn oil) daily, beginning
on the first day of the DSS cycle.

Histopathological colitis score
Formalin-fixed colon tissue was embedded in paraffin and cut into 5 μm thick sections.
Next, the colon sections were stained using hematoxylin and eosin (H and E). Four
randomly chosen, non-overlapping fields of each stained section were analyzed and
assigned a colitis severity score by a pathologist using methods described
previously[34,35]. In short, the degree of colitis was scored on the basis of the following
parameters: Extent of the injury (0, none; 1, mucosa; 2, mucosa and submucosa; and 3,
transmural), inflammation severity (0, none; 1, mild; 2, moderate; and 3, severe), and
crypt damage (0, none; 1, basal one-third damaged; 2, basal two-thirds damaged; 3,
crypt loss and the presence of surface epithelium; and 4, loss of the entire crypt and
epithelium). Then the degrees for each of these aforementioned parameters were
multiplied by an extent score that represented the percentage of each parameter that
had a given feature as follows: 1, 0-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%. We
defined the total score as the sum of the three parameters. The bottom limit total colitis
score was 0; the upper limit total

Characterization of CD4+ T cells in the mesenteric lymph node and spleen
For flow cytometry, the mesenteric lymph nodes (MLN) and spleens were pooled from
each group of mice and placed in ice-cold medium. These tissues were mechanically
disrupted, teased into single-cell suspensions, filtered through a cell strainer (70 μm),
and placed in complete medium (RPMI-1640 containing 100 mL/L of heat-inactivated
fetal bovine serum). The isolated cell suspension was stimulated with a cell
stimulation cocktail (eBioscience™) plus protein transport inhibitors (Invitrogen,
catalog 00-4975), for 4-6 h. Stimulated cells were incubated with anti-CD4 mAb and
anti-CD25 mAb for 15 min on ice (Biolegend, United States). For intracellular cytokine
staining, the cell suspension was incubated with anti-IFNγ, Interleukin-17 after
treating the cells with Fixation/permeabilization kit (BD Biosciences catalog 554714).
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For Treg identification, we used FOXP3/Transcription Factor Staining Buffer set
(eBioscience Invitrogen) before adding anti-FOXP3. Staining and washing were carried
out in complete medium on ice. The stained cells were analyzed with a Beckman
Coulter FC500 flow cytometer.

Enzyme linked immunosorbent assays
Interleukin-17 (IL-17), IL-6, IL-10, IL-4, IL-6, IL-21, IL-22, IL-23, IL-1β, transforming
growth factor beta 1 (TGF-β1) , tumor necrosis factor-alpha (TNF-α) and interferon
gamma (INF-γ), in the plasma and/or in colonic tissue lysates were quantified by
ELISA kits (R and D Systems, Minneapolis, MN, United States) following the
manufacturer’s recommendations. Colon tissues were prepared for ELISA as described
previously[33]. Briefly, the mouse colons where washed immediately with cold
phosphate buffered saline and frozen at -70°C until use. The samples were
homogenized in 200 µL protein analysis buffer [10 mL of 1 mol/L Tris-hydrochloric
acid (pH 8.0), 6 mL of 5 mol/L sodium chloride and 2 mL of Triton X-100 to 182 mL of
sterilized distilled water][33] in 2 mL microcentrifuge tubes with a 0.9-2.0 mm stainless
steel bead blend and homogenized with a tissue homogenizer (MP FastPrep-24) at a
speed of 0.4 m/s for 20 s. Samples were frozen and thawed, and homogenized three
times, then centrifuged at 30000 g for 30 min at 4°C. The supernatant was collected,
and the pellet was re-suspended in phosphate buffer. Protein concentrations were
determined using a bicinchoninic acid assay (Bio-Rad). Samples were frozen until the
ELISA assays were performed and 0.5-1.0 mg/mL of protein was used for each run,
depending on the interleukin type.

Sample collection and RNA isolation
Mesenteric lymph nodes were collected from the groups on the day of the sacrifice and
immediately frozen at -70°C prior to use. Mesenteric lymph nodes were ground with
mortar and pestle in liquid nitrogen. QIAzol Lysis Reagent (Qiagen, catalog 217004)
was added to the samples and they were then homogenized by MP FastPrep-24 with
0.9-2.0 mm stainless steel beads (0.4 m/s for 10 s). Total RNA, including mRNA,
miRNA and other small RNA molecules, were isolated from all the mesenteric lymph
node with the miRNeasy Kit (Qiagen, Germany), following the manufacturer's
procedure. The concentration and purity of the isolated RNA was determined using a
Beckman Coulter DU800 UV/visible spectrophotometer. RNA quality was assessed by
measuring the absorbance (A260/A280, A260/A230) of isolated samples and by
agarose gel electrophoresis.

MicroRNA array analysis
The microarray was performed at the University of South Carolina School of Medicine
following the protocol described by Bam et al[36,37]. Briefly, total RNA isolated as
described above was hybridized to an Affymetrix miRNA-v3 gene chip (Affymetrix,
Sunnyvale, CA, United States) as directed by the manufacturer. Raw data was
processed in the Transcriptome Analysis Console (Affymetrix). The heat map was
generated in Genesis[38]. The data from Transcriptome Analysis Console were used to
calculate the linear fold-change of the expression of miRNAs to compare the miRNA
expression differences among treatment groups. A linear fold-change of at least ± 1.5
was used as a cutoff value for the inclusion of a miRNA for further analysis. Moreover,
only the miRNAs which were significant on the basis of P value (< 0.05) calculated
using student’s t-test, were included in the analysis.

MiRNA-target gene prediction
Ingenuity Pathway Analysis (IPA, Qiagen, Redwood City, CA, United States) was
used to predict the targets of the differentially expressed miRNAs. Networks relevant
to regulatory T cells were generated to identify relevant miRNA species for testing.
Other databases [TargetScan (http://www.targetscan.org/vert_72/), miRWalk (
http://mirwalk.umm.uni-heidelberg.de/)] were also used to identify genes targeted
by specific miRNAs.

Quantitative real-time PCR analysis of miRNA and gene expression
Total RNA from MLN was isolated and purified with the miRNeasy Kit (Qiagen,
Valencia, CA, United States), following the manufacturer's procedure. The miScript II
RT complementary DNA (cDNA) synthesis kit (Qiagen, Germany) was used according
to the manufacturer's specifications to reverse-transcribe cDNA by taking 1 μg each of
total RNA in a 20 μL total volume. The quantitative real-time (qRT-PCR) reactions
were carried out using miScript Primer Assays or miScript Precursors (Qiagen,
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Germany) according to manufacturer instructions. U6, SnorD96, Snor68, Snor234, and
Snor202 were evaluated for stability among groups and SnorD96 was chosen for
normalization. SnorD96 has also been used by others[39,40]. Primers were purchased
from Qiagen, Maryland.
For mRNA expression analysis, cDNA was made from total RNA as described. A
two-step amplification qRT-PCR was carried out using SsoAdvanced™ SYBR® green
supermix from Bio-Rad (Hercules, CA, United States) with the mouse primers shown
in Table 1. The real-time PCR conditions were as follows: Initial step at 95°C for 10 s
followed by cycles (n = 40) consisting of 30 s at 95°C, followed by 30 s annealing/extension at 60°C and a final extension step for 30 s at 72°C. Data are
normalized to expression of the reference gene encoding β-actin. Primers were
purchased from Integrated Technologies and from Invitrogen. Melting temperatures
ranged from 56.0°C to 64.5°C. Primer efficiency was measured for each primer set. All
reactions were performed in triplicate. The qPCR experiments were carried out on a
CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, United
States). Fold changes were calculated using the 2−ΔΔCT (Livak) method.

Statistical analysis
Significance of differences between groups at single time points were determined
using the Mann-Whitney U-test using GraphPad Prism software (Version 8.2). P
values less than 0.05 were considered significant. Colitis symptom time course data
were analyzed using a repeated measure analysis with 13 measures taken per animal
(day one to day thirteen) randomly assigned to six groups (Ctrl, H. muridarum, H.
muridarum/DSS, H. muridarum/DSS/I3C, DSS/I3C) and three experiments.
Descriptive statistics were computed on the variables. For categorical variables, the
univariate constructions will be included frequency distributions. For continuous
variable statistics included measure of central tendency (mean and median) and
measure of spread (standard deviation and range). Descriptive statistics for main
variables were carried out for each group. In the analysis, expected mean squares were
calculated and the appropriate combination used for hypothesis tests with specific
functions of the repeated measures. General linear model analyses in SAS (MIXED
procedure) were used to examine the effects of day, group, and day by group
interaction. Post-hoc comparisons for the appropriate effects were examined. In
addition, parameter estimates of the effects of covariate (experiment) and of the
appropriate structure for the repeated observations was estimated. Adjusted TukeyKramer multiple comparison was used for significant effects. Significance levels are
indicated as aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001; dP ≤ 0.0001.

RESULTS
Exacerbation of colitis by H. muridarum is counteracted by I3C treatment
In three independent experiments, female wild-type C57BL/6 mice were infected with
live H. muridarum bacteria seven, five, three, and one days prior to commencement of
DSS treatment (day zero). Pathology in mice treated with 30 g/L DSS was so severe
that one H. muridarum/DSS treated mouse required euthanasia. For this reason, 10 g/L
DSS was used in subsequent experiments. Figure 1 shows average values from three
independent experiments. Statistical analysis results are shown in Table 2 and Table S1
. Overall disease activity was increased by each treatment except H. muridarum when
compared to the control group. H. muridarum alone occasionally induced stool
softening and a small amount of fecal occult blood, yet H. muridarum decreased
diarrhea scores in DSS-treated mice (Figure 1A and Table 2). On the other hand, H.
muridarum increased fecal occult blood and weight loss in DSS-treated mice. I3C was
as effective in ameliorating colitis symptoms in H. muridarum mice as it was in
uninfected mice. Significant shortening of the colon, an indicator of inflammation,
occurred in H. muridarum-infected mice compared with control mice (Figure 1B). DSS
treatment of H. muridarum mice caused additional shortening and colon length was
similar to DSS mice. I3C significantly increased colon length in both infected and
uninfected mice. It is evident from the pathology scores that the infection with H.
muridarum alone can induce pathology such as dilatation of glandular crypts, edema,
and destruction of epithelium and glands (Figure 1B). In some cases, pathology caused
by H. muridarum alone is comparable to that caused by DSS treatment, yet damage to
the mucosa was not reflected in symptom scores in these mice. Treatment of H.
muridarum-infected mice with DSS further worsened pathology.
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Table 1 Primers used for transcription analysis
Gene

Forward primer (5’-3’)

Reverse primer (5’-3’)

Actb (β-actin)

TCACCCACACTGTGCCCATCTACG

CAGCGGAACCGCTCATTGCCAATGG

Il17a

TCAGCGTGTCCAAACACTGAG

CGCCAAGGGAGTAAAGACTT

Foxp3

AGCAGTCCACTTCACCAAGG

GGATAACGCCAGAGGAGCTG

Rorc

CCGCTGAGAGGGCTTCAC

TGCAGGAGTAGGCCACATTACA

Il10

TGAATTCCCTGGGTGAGAAGC

ATCACTCTTCACCTCCAC

Il6

AGCCAGAGTCCTTCAGAGAGAT

AAAAAGTGCCGCTACCCTGA

Table 2 Colitis symptom score P values
Treatment groups2
Ctrl vs

Hm vs

Hm/DSS vs

DSS vs

% Weight

Stool blood
1

Diarrhea
1

DAI

Hm

0.2495

0.6142

0.0248

0.06591

Hm/DSS

< 0.00011

< 0.00011

< 0.00011

< 0.00011

Hm/DSS/I3C

0.9574

< 0.00011

< 0.00011

< 0.00011

DSS

0.0552

< 0.00011

< 0.00011

< 0.00011

DSS/I3C

0.1381

< 0.00011

< 0.00011

< 0.00011

DSS

0.9823

< 0.00011

< 0.00011

< 0.00011

Hm/DSS

< 0.00011

< 0.00011

< 0.00011

< 0.00011

DSS

< 0.00011

0.00071

0.00411

< 0.00011

Hm/DSS/I3C

< 0.00011

< 0.00011

< 0.00011

< 0.00011

DSS/I3C

0.9977

0.00261

< 0.00011

< 0.00011

1

Significant P values.
Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter muridarum plus DSS plus I3C; DSS/I3C:
DSS plus I3C.
2

Effects of H. muridarum, DSS, and I3C on miRNA expression
Since miRNAs contribute to immune cell differentiation, we sought to determine
which miRNAs were regulated by I3C, which were regulated by H. muridarum, and
whether H. muridarum affected the I3C response. To accomplish this, we performed
miRNA analysis on total RNA isolated from the mesenteric lymph nodes of all groups
from one of the experiments. A heat map was constructed highlighting the differences
in miRNA abundance among the groups (Figure 2A). We found that each group had a
pattern that was distinct from all others. For example, H. muridarum infection alone
altered miRNA expression and miRNA expression in DSS, I3C treated mice was
different depending on whether they were infected or uninfected.
We sought to determine whether I3C-regulated miRNAs are associated with
regulation of the major Treg and Th17 transcriptional regulators, FOXP3 and RORC.
To this end, we used in silico analysis of predicted miRNA targets and pathways as
well as online databases to search for miRNAs induced by I3C in H. muridarum /DSS
mice that could target Foxp3 and Rorc genes. Among these potential miRNAs, we
identified 3 candidates that had acceptable alignment scores and were highly
predicted to target Foxp3 or Rorc. These miRNAs included miR-let7a-5p and miR-29a3p, which target RORC, and miR-874-5p and miR-6906-5p, which target FoxP3. It
should be noted that other members of the let-7 family also target Rorc and some were
similarly regulated by I3C in H. muridarum-infected mice. We performed qRT-PCR on
cDNA samples reverse transcribed from total MLN RNA. As predicted, we found
increased expression of miR-23a-3p and let-7a-2, which target Rorc (Figure 2B).
Differences between untreated and I3C-treated groups were only significant for H.
muridarum-infected mice, but the Rorc-targeted miRNAs miR-29a-3p and let-7a
trended higher in uninfected mice. We also found that I3C decreased expression of
Foxp3-targeting miR-874-5p and miR-6906-5p in H. muridarum-infected mice, but only
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Figure 1 Symptom scores and histopathology. A: Colitis symptom scores (n = 17-21 per group); B: Colon length (n = 17-21 per group) and histopathology
scores (n = 7 per group). aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001; dP ≤ 0.0001. Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS;
Hm/DSS/I3C: Helicobacter muridarum plus DSS plus I3C; DSS/I3C: DSS plus I3C.

miR-6906-5p was reduced in uninfected mice. This is not surprising since miR-874-5p
was not predicted to be elevated by DSS in uninfected mice, but it highlights the
different miRNA responses seen among groups. The miRNAs miR-15b and miR-16
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Figure 2 MicroRNA expression analysis. A: A heat map of expression intensities for each group was generated using Genesis software with red representing
high expression and green representing low expression; B: Expression of microRNA as determined by quantitative real time PCR. All values are normalized to
expression in the control group (n = 7); and C: Venn diagrams generated using Venny 2.1 demonstrate microRNA expression changes common to different treatment
conditions. aP ≤ 0.05; bP ≤ 0.01. Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter muridarum plus
DSS plus I3C; DSS/I3C: DSS plus I3C.

support Treg development by targeting a suppressor of Treg development and miR15b/16 previously have been shown to be induced by DIM[41,42]. We also found these
miRNAs to be increased by I3C in H. muridarum-infected, DSS-treated mice (Figure S1
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), but their expressions were predicted to be oppositely regulated in uninfected mice.
A closer look at miRNA microarray data was illuminating. The first Venn diagram
shown in Figure 2C highlights miRNAs that displayed a greater than 2-fold change in
the colitis groups compared with the control group. The H. muridarum group has 679
miRNAs up or down-regulated compared with the control, vs 666 miRNAs in the DSS
group, and 722 miRNAs in the H. muridarum /DSS group. Interestingly, the majority (
n = 574) of the miRNA changes are shared between the H. muridarum group and the
DSS group and most of these (n = 543) are also shared with the H. muridarum /DSS
group as well. This demonstrates that the miRNA response to H. muridarum infection
is very similar to the response induced by DSS treatment. More importantly, miRNAs
common between the H. muridarum group and the DSS group were almost all
regulated in the same direction. All miRNA data are found in Table S2.
A second Venn diagram further highlights the effect of DSS treatment by
substituting the H. muridarum /DSS vs H. muridarum comparison for the H. muridarum
vs control comparison. Not surprisingly, the number of miRNAs changed between H.
muridarum /DSS and H. muridarum (n = 281) is much smaller than the effect of H.
muridarum /DSS compared to Ctrl (n = 722), but the majority of those miRNAs (69.8%)
are also altered by DSS. It should be noted that 80.1% of the miRNAs altered by DSS
treatment of H. muridarum mice are found within the H. muridarum /DSS vs Ctrl
comparison. 85.7% if miRNAs common between DSS vs Ctrl and H. muridarum/DSS vs
H. muridarum were concordant in the direction of change. This recapitulates the
findings shown in the first Venn diagram, indicating that H. muridarum infection and
DSS treatment have similar effects.
A third Venn diagram was constructed to study the effects of I3C treatment. In I3Ctreated animals (Figure 2C), there was less overlap between H. muridarum-infected and
–uninfected animals (87 miRNAs, or 23.5%). Oddly, most of the 87 common miRNAs
(71.2%) were oppositely regulated in H. muridarum-infected and uninfected mice. In
most cases, miRNAs were upregulated by I3C in H. muridarum-infected mice, but
downregulated by I3C in uninfected mice. The predicted fold changes were also larger
in H. muridarum-infected mice. The reason for this odd regulation pattern is discussed
in the next paragraph. An alternative method for Identifying I3C effects is to compare
H. muridarum /DSS/I3C vs control with DSS/I3C vs Ctrl (Figure 2C). These miRNA
populations overlap heavily (73.1%). Most of the 87 previously identified miRNAs
(56/87) are found in the overlap group. Since there is also heavy overlap between the
putative I3C-regulated miRNAs and DSS-regulated miRNAs (529/666), it is not clear
whether any of the miRNAs are strictly responsive to I3C; however, the overlap is
consistent with the hypothesis that I3C normalizes miRNAs involved in colitis.
Examination of specific miRNAs provides a clearer demonstration of the effects of
H. muridarum, DSS, and I3C and an explanation for the differential regulation of
miRNAs by I3C in infected vs uninfected mice. We examined a list of 45 miRNAs that
are altered in human IBD[43-45]. Almost all of the human IBD-associated miRNAs were
altered by H. muridarum and/or DSS. Table 3 shows raw expression data and fold
changes for the selected miRNAs. When compared with control values, these miRNAs
were all downregulated, whereas many were upregulated compared to healthy
controls in humans[43]. Possible reasons for this are discussed later. Expression
decreases are mostly modest in H. muridarum vs Ctrl, but extreme in H. muridarum
/DSS vs Ctrl- up to 3,646-fold decreased. The expression reductions were less extreme
in the H. muridarum /DSS/I3C group compared to Ctrl. Expression of the selected
miRNAs was lower in DSS/I3C group than the DSS group, but in many cases, the
reductions were less than two-fold, which is why those miRNAs did not show up as
common between infected and uninfected mice treated with I3C. It should be noted
that there was not a global decrease in miRNA expression in any treated groups vs
Ctrls; the decreases are specific to certain miRNAs. All 45 human IBD-associated
miRNAs were among the 576 miRNAs in the putative I3C regulated group (Figure 2C)
and all but two of the 45 were regulated by H. muridarum and/or DSS. Bian et al[46] also
reported that many of these miRNAs are differentially regulated in DSS-treated mice,
suggesting that a core set of miRNAs are relevant to colitis in both humans and
mice[46].

H. muridarum infection alters T helper cell profiles.
Since miRNAs are pleotropic in their effects, we sought to confirm predicted effects on
Treg and Th17 populations. MLN transcript analysis by qRT-PCR demonstrated that
I3C decreased RORC and increased FOXP3 expression, consistent with a switch from
Th17 to Treg (Figure 3). These results were mirrored by the decrease in IL17 and
increase in IL10 expression. Expression of Il6, which is involved in Th17 induction, is
also shown. RORC and IL17 were more strongly induced by DSS in H. muridarum-
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Table 3 MicroRNA expression
Raw expression data

Fold changes

miRNA

Ctrl

Hm

Hm/DSS

DSS/Hm/ I3C

DSS

DSS/ I3C

Hm vs Ctrl

Hm/DSS vs Ctrl

DSS/Hm/I3C vs Ctrl

DSS vs Ctrl

DI vs Ctrl

DMI vsDHM

DI vs DSS

mmu-let-7a-5p

12.93

11.14

5.72

9.11

10.71

10.59

-3.45

-147.58

-14.06

-4.65

-5.07

10.5

-1.09

mmu-let-7b-5p

14.14

11.84

7.97

10.45

11.21

10.89

-4.92

-72.01

-12.96

-7.62

-9.56

5.56

-1.25

mmu-let-7d-5p

13.76

11.52

8.09

10.44

11.1

10.86

-4.71

-50.67

-9.97

-6.29

-7.42

5.08

-1.18

mmu-let-7e-5p

11.06

10.06

1.7

8.39

9.6

9.23

-2

-654.64

-6.34

-2.74

-3.54

103.31

-1.29

mmu-let-7g-5p

10.31

6.71

1.37

2.01

7.52

6.16

-12.19

-491.93

-317.1

-6.92

-17.81

1.55

-2.58

mmu-miR-103-3p

11.85

10.44

6.42

10.09

10.88

10.02

-2.66

-43.07

-3.39

-1.96

-3.57

12.7

-1.82

mmu-miR-106a-5p

9.29

5.45

1.15

2.03

5.51

2.78

-14.34

-282.96

-153.91

-13.78

-91.54

1.84

-6.64

mmu-miR-127-3p

7.9

4.55

0.95

2.8

2.43

1.91

-10.18

-123.98

-34.2

-44.34

-63.55

3.63

-1.43

mmu-miR-128-3p

5.81

0.79

0.94

1.04

0.77

1.3

-32.4

-29.23

-27.31

-33.04

-22.87

1.07

1.44

mmu-miR-135a-1-3p

3.64

1.3

1.8

1.26

1.43

2.12

-5.04

-3.57

-5.19

-4.62

-2.86

-1.45

1.62

mmu-miR-140-3p

10.2

9.92

1.83

7.91

9.62

8.3

-1.21

-329.16

-4.87

-1.49

-3.73

67.62

-2.51

mmu-miR-140-5p

6.33

1.38

0.79

1.02

1.38

0.87

-30.86

-46.56

-39.48

-30.86

-43.84

1.18

-1.42

mmu-miR-142-5p

2.9

0.99

1.35

0.99

1.16

1.01

-3.78

-2.93

-3.78

-3.34

-3.72

-1.29

-1.11

mmu-miR-145a-5p

12.99

11.51

6.79

10.2

11.15

10.28

-2.78

-73.5

-6.89

-3.57

-6.55

10.66

-1.83

mmu-miR-146a-5p

10.34

7.84

1.24

3.54

7.72

7.84

-5.65

-550.48

-111.6

-6.13

-22.7

4.93

-3.7

mmu-miR-150-5p

13.4

11.1

4.14

8.96

10.4

9.76

-4.92

-614.48

-21.78

-8.01

-12.51

28.22

-1.56

mmu-miR-155-5p

9.86

8.15

1.54

3.58

7.65

5.31

-3.27

-320.03

-77.72

-4.61

-23.48

4.12

-5.09

mmu-miR-15b-5p

11.17

10.17

1.48

8

9.92

8.84

-1.99

-824.5

-9.01

-2.37

-5.02

91.56

-2.12

mmu-miR-16-5p

13.18

10.38

1.35

9.1

10.8

9.11

-7

-3646.25

-16.92

-5.22

-16.9

215.51

-3.23

mmu-miR-17-5p

10.71

9.01

1.33

7.8

9.29

7.82

-3.25

-666.3

-7.53

-2.67

-7.43

88.54

-2.78

mmu-miR-185-5p

9.27

6.58

0.99

5.64

5.86

5.07

-6.45

-310.71

-12.33

-10.58

-18.36

25.19

-1.74

mmu-miR-18a-5p

7.32

1.37

0.84

1.37

1.41

1.74

-61.84

-89.41

-61.84

-60.29

-47.91

1.45

1.26

mmu-miR-195a-5p

10.59

8.03

1.91

5.03

8.22

7.39

-5.89

-409.38

-47.19

-5.17

-9.14

8.68

-1.77

mmu-miR-196b-5p

3.11

0.94

0.94

1.08

1.05

0.83

-4.49

-4.49

-4.09

-4.19

-4.86

1.1

-1.16

mmu-miR-199a-5p

9.5

4.56

1.77

2.01

7.72

1.77

-2.03

-101.88

-21.49

-3.71

-78.21

4.74

-21.08
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mmu-miR-19a-3p

4.08

1.56

1.39

0.91

1.24

1.25

-5.73

-6.45

-9.02

-7.15

-7.13

-1.4

1

mmu-miR-19b-3p

9.43

6.13

1.18

5.87

7.97

5.61

-9.84

-303.99

-11.79

-2.74

-14.07

25.78

-5.14

mmu-miR-20b-5p

9.03

4.87

1.76

2.29

5.85

1.96

-17.77

-154.33

-106.75

-9.05

-133.96

1.45

-14.8

mmu-miR-221-3p

9.19

6.07

1.24

1.42

7.45

5.25

-8.65

-246.56

-218.06

-3.34

-15.34

1.13

-4.59

mmu-miR-222-3p

8.89

7.65

1.12

4.11

6.24

4.58

-2.36

-219.12

-27.5

-6.29

-19.86

7.97

-3.16

mmu-miR-223-3p

5.45

1.57

1.01

0.99

1.84

0.87

-14.69

-21.58

-21.99

-12.14

-23.85

-1.02

-1.96

mmu-miR-24-2-5p

12.74

10.84

1.78

9.51

10.8

10.12

-56.17

-101.73

-64.83

-72.38

-48.35

1.57

1.5

mmu-miR-27a-3p

9.96

5.94

1.35

1.57

8.22

5.2

-16.28

-390.62

-337.26

-3.34

-27.11

1.16

-8.12

mmu-miR-28a-3p

7.53

4.75

0.83

1.4

1.49

1.12

-6.86

-103.85

-69.7

-65.83

-84.8

1.49

-1.29

mmu-miR-29a-3p

10.97

8.84

2.38

7.73

9.45

7.38

-4.37

-386.19

-9.45

-2.86

-12.06

40.85

-4.21

mmu-miR-29c-3p

5.38

0.87

1.23

1.28

2.05

1.8

-22.8

-17.81

-17.22

-10.08

-12.01

1.03

-1.19

mmu-miR-30e-5p

7.8

1.13

1.64

1.64

3.46

1.32

-101.76

-71.46

-71.46

-14.68

-89.04

1

-4.42

mmu-miR-345-5p

5.41

2.46

2.85

3.65

2.81

1.18

-7.76

-5.93

-3.41

-6.1

-18.84

1.74

-3.09

mmu-miR-374b-5p

4.34

0.92

1.19

0.89

1.58

1.13

-10.7

-8.87

-10.91

-6.78

-9.23

-1.23

-1.36

mmu-miR-423-5p

7.07

3.13

1.29

4.25

2.56

1.26

-15.33

-54.69

-7.03

-22.66

-55.78

7.78

-2.46

mmu-miR-491-5p

2.95

1.39

1.15

1.01

1.34

1.07

-2.96

-3.49

-3.84

-3.06

-3.7

-1.1

-1.21

mmu-miR-532-5p

8.4

5.55

0.89

3.43

3.45

1.75

-7.22

-183.34

-31.45

-30.94

-101.04

5.83

-3.27

mmu-miR-760-3p

2.44

0.99

0.74

1.1

1.15

1.17

-2.73

-3.25

-2.54

-2.46

-2.42

1.28

1.02

mmu-miR-877-5p

4.05

3.56

1.93

2.14

3.28

1.8

-1.4

-4.35

-3.75

-1.7

-4.76

1.16

-2.79

mmu-miR-93-5p

10.41

8.67

1.86

7.64

8.66

6.85

-3.34

-373.43

-6.79

-3.35

-11.77

54.98

-3.52
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Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter muridarum plus DSS plus I3C; DSS/I3C: DSS plus I3C.

infected mice than in uninfected mice, consistent with the increased pathology.
Although FOXP3 was less strongly induced by I3C in H. muridarum-infected mice, IL10
expression was similar to that of uninfected mice treated with I3C. These results were
corroborated by flow cytometry (Figure S2). The Th17 cell population increased
sharply following DSS treatment of H. muridarum-infected animals and decreased
following I3C treatment while the Treg population increased.

Production of cytokines in colon tissue and plasma
Our gene expression and flow cytometry data from the mesenteric lymph nodes
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Figure 3 Expression of T helper 17 and Treg-associated genes in mesenteric lymph nodes. Gene expression was determined from total
complementary DNA using qRT-PCR and values were normalized to the control group (n = 7). aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001. Ctrl: Control; Hm: Helicobacter
muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter muridarum plus DSS plus I3C; DSS/I3C: DSS plus I3C.

clearly show that DSS and H. muridarum shift the T helper cell profile towards a Th17dominated response, whereas I3C increases the Treg population. We next measured
cytokine concentrations in colon homogenates to assess local immune cell and
epithelial responses. These measurements encompass both epithelial cells and
inflammatory cells. In most cases, production of pro-inflammatory cytokines was
altered by multiple variables. Infection with H. muridarum alone increased all proinflammatory cytokines tested except IL-17 and IL-23 compared with control mice
(Figure 4). In fact, cytokine levels in H. muridarum-infected mice were similar to those
in uninfected, DSS-treated mice. Treatment of H. muridarum-infected mice with DSS
caused trends towards further increases in most cytokines, but this was only
significant in the case of IL-17. I3C treatment reduced secretion of all proinflammatory cytokines in DSS-treated, H. muridarum-infected and/or uninfected
mice.
Levels of the anti-inflammatory cytokines IL-10 and TGFβ were only significantly
altered by I3C, though TGFβ levels trended lower in DSS-treated mice (Figure 4).
There were trends towards decreased IL-4 levels in uninfected mice treated with I3C,
but not in H. muridarum infected mice treated with I3C. To summarize, I3C both
decreases secretion of pro-inflammatory cytokines an increases secretion of anti-
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Figure 4 Colon cytokine production. Protein levels were determined by ELISA using colon homogenates (n = 17-21). aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001; dP ≤
0.0001. Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter muridarum plus DSS plus I3C; DSS/I3C:
DSS plus I3C.

inflammatory cytokines.
Plasma cytokines showed less dramatic changes than colon cytokines, the
proinflammatory IL-17 and IL-6 cytokine concentrations were elevated in the H.
muridarum /DSS group and to a lesser extent in the DSS group. I3C treatment reduced
both to control levels. IL-10 was elevated by I3C in H. muridarum-infected mice and
trended higher in the DSS/I3C group (Figure 5). TGFβ was reduced only in H.
muridarum-infected mice and did not respond to I3C treatment. IL-4 and IL-22 were
not significantly altered under any condition (Figure S3). Serum amyloid a levels were
significantly increased only in H. muridarum /DSS mice, consistent with more severe
pathology in that group. The neutrophil marker myeloperoxidase was strongly
increased by H. muridarum infection, even in the absence of DSS treatment (Figure 5).

DISCUSSION
Effects of H. muridarum on susceptibility to DSS-induced colitis and treatment with
I3C
Several models of inflammation and inflammatory bowel disease suggest that bacteria
are necessary, but insufficient triggers of IBD[47] and several studies have reported that
EHH species modulate IBD. As an example, H. macacae has been connected with
chronic idiopathic colitis in young rhesus macaques and a study of children with CD
reported PCR evidence for Helicobacter infection in 59% of patients vs 9% of healthy
controls[11,48]. Similarly, Laharie et al[10] found that H. pullorum or H. canadensis infection
was considerably related to CD in adults[10]. Finally, H. canis, another EHH species, has
been detected in duodenal ulcerations associated with CD[49]. Therefore, certain
Helicobacter species are almost certainly involved in IBD pathogenesis; however, the
exact mechanism of EHH involvement remains undiscovered.
Th17 cells have a crucial role in colitis development in both humans and mouse
models[50,51]. H. pylori is known to induce a Th17 response in the gastric mucosa[52-54], yet
H. pylori infection is associated with a decreased risk of IBD[55]. H. pylori only colonizes
the gastric mucosa, meaning that any effects of H. pylori on the colon are likely due to
systemic effects of infection. Furthermore, EHH species lack the major H. pylori
virulence factors cagA and vacA. Thus, one cannot assume that mucosal or immune
effects of H. pylori infection will match those caused by EHH species. It is therefore
necessary to use infection with EHH species to investigate potential mechanisms of
EHH-mediated contributions to IBD.
The present study extends existing knowledge on H. muridarum pathogenesis. H.
muridarum infection has been previously shown to induce colitis in C57BL/6 mice
treated with DSS and in monoassociated severe combined immunodeficiency mice
following the transfer of certain T cell populations[13,35,56]. We found increased weight
loss and stool blood in H. muridarum-infected mice treated with DSS compared with
DSS treatment alone, but diarrhea was actually lessened. Increased stool blood
suggests damage to the mucosal barrier, potentially increasing exposure to other
members of the gut microbiota. Though H. muridarum alone did not cause appreciable
colitis symptoms, it caused modest colon shortening and inflammatory infiltrates.
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Figure 5 Plasma cytokine and inflammatory protein markers. Protein levels were determined by ELISA using plasma collected at the time of euthanasia (
n = 5-7). aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001. Ctrl: Control; Hm: Helicobacter muridarum; Hm/DSS: Helicobacter muridarum plus DSS; Hm/DSS/I3C: Helicobacter
muridarum plus DSS plus I3C; DSS/I3C: DSS plus I3C.

Effects of H. muridarum, DSS, and I3C on microRNA expression
There is increasing interest in the use of miRNAs to diagnose and treat a wide variety
of diseases and cancers. We examined mesenteric lymph node miRNA expression to
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determine whether miRNA signatures explained the effects of H. muridarum and I3C.
Many studies show that miRNAs participate in the regulation of crucial lymphocyte
functions such as lymphocyte development, maturation, activation, and
differentiation[19,28,57,58]. When considering the roles of miRNAs in Treg and Th17
function, it is necessary to distinguish between miRNAs involved in T cell
differentiation and miRNAs involved in function. For example, miRNAs binding to
the Treg transcriptional regulator gene FOXP3 prevent differentiation of Tregs and
must be downregulated to allow Treg differentiation. Some miRNAs promote FoxP3
expression by downregulating expression of other genes, while others are induced by
FoxP3 and influence Treg function. Still other miRNAs act in an autocrine manner,
being both induced by FoxP3 and inducing FOXP3 expression[59]. Therefore, miRNA
expression patterns can differ between naïve and mature T cells and between highly
active and anergic T cells. A further complication of miRNA interpretation is that the
same miRNA can have different effects depending on the cell type in which it is
expressed. For example, miR-155 reportedly induces both Treg and Th17 cell
differentiation[60] making it impossible to predict whether increased miR-155 in the
lymph node, or even within the T cell population, favors a Treg or Th17 phenotype.
Relative concentrations of miRNAs within each cell most likely dictate the cell
phenotype.
These nuances explain the often disparate and contradictory results published in the
literature. For example, Iborra et al[43] sought to compare serum and mucosal miRNAs
profiles in human ulcerative colitis and Crohn’s disease[43]. They found little overlap
between serum and tissue miRNAs and many differences between their results and
those published by others. Each miRNA has hundreds or thousands of targets[61] and
each gene is likely controlled by dozens of miRNAs. In the context of IBD and colon
cancer, miR-15b/16 is reported to regulate Tregs, macrophages, TP53, aquaporin 8,
and the adenosine A2a receptor[41,62-65]. Surprisingly, miR-16 has even been suggested as
a stable reference miRNA[66]. The multiple targets of miR-15b/16 may then explain
why treatment of mice with miR-16 precursors ameliorates colitis, yet elevated miR-16
in human blood samples is associated with more severe IBD[62,67,68].
Interpretation of miRNA data in our study proved similarly challenging; however,
there was remarkable overlap between the responses to H. muridarum, DSS, and I3C.
Nonetheless, the direction of regulation was not always as expected. For example,
when looking at a set of colitis-associated miRNAs, expression dropped following
treatment with either H. muridarum or DSS, whereas human studies found increases in
these miRNAs in IBD patients vs controls[43-45]. The human studies used either
peripheral blood or colon biopsies as a source of miRNAs, whereas we used
mesenteric lymph nodes. Lymph nodes differ in cellular composition compared to
peripheral blood[69] and since the cell subsets change following H. muridarum infection
or DSS treatment, the ratios of T cells to dendritic or other cell populations may change
as well. Because colitis-associated miRNAs are likely expressed in multiple cell types,
the meaning of a miRNA increase or decrease cannot be deciphered without knowing
whether they rise or fall in each cell subtype. Presorting cells by flow cytometry would
provide better data for understanding the effects of miRNA expression changes, but
would not be feasible for most clinical samples due to the limited amounts of tissue
available.
One would think that if DSS or H. muridarum decreases miRNA expression, then I3C
treatment should increase it back to the control value. This was not necessarily the case
for the same reasons mentioned above. I3C increased the number of cells found in
MLN, and likely the ratios of cell types. The fact that I3C altered roughly the same
subset of miRNAs as DSS or H. muridarum is consistent with its known antiinflammatory effects, but does not shed light on the mechanism of I3C activity. Rather,
the results are consistent with the hypothesis that miRNA changes due to I3C result
from, rather than cause, immune response normalization.
We did not find measurable effects of H. muridarum infection alone on cytokine
expression in the lymph nodes or on plasma cytokine levels; however, there were clear
pro-inflammatory changes in the colon, which were further exacerbated by DSS
administration. The cytokines induced by H. muridarum (TNFα, IL-1β, IL-6, and IFNγ)
are typical of those induced by DSS treatment[17]. It is therefore not surprising that H.
muridarum further increased production of inflammatory cytokines and worsened
pathology following DSS treatment. In humans with IBD, increases in mucosal TNFα,
IL-1β, IL-6, IL-23 and IFNγ are due to lamina propria monocytes or macrophages[70-72].
IFNγ is also produced by Th1 cells or potentially a new intraepithelial lymphocyte
subtype, IL-17+ IFNγ+ T cells[73]. Regardless of cell source, IFNγ plays an important role
in IBD pathology in humans and mice[74,75]. Thus, the effects of H. muridarum in our
mouse model will likely be relevant to humans infected with enterohepatic species. In
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general, H. muridarum infection more strongly influenced production of
monocyte/dendritic cell-associated cytokines (TNFα, IL-1β, IL-6 , IL-23) compared to T
cell-associated cytokines (IFNγ, IL-4, IL-10, IL-17, IL-21, IL-22), although IFNγ was
increased by H. muridarum alone.
Cytokines secreted by monocytes or dendritic cells can drive T cell differentiation.
TGFβ and IL-6 can drive several differentiation pathways depending upon which
other cytokines are present[76]. The combination TGFβ, IL-6, and IL-23 efficiently
induce Th17 differentiation[77]. In spite of local cytokine responses suggestive of a
Th17-promoting milieu, we did not find evidence of a substantial T cell shift in mice
infected with H. muridarum alone. DSS treatment was required for enhanced
expression of RORC and IL17 in lymph nodes or increased plasma IL-17. In contrast,
there was no apparent difference in Treg markers in lymph nodes or plasma between
infected and uninfected mice. These data suggest that local effects of H. muridarum are
conducive to, but not sufficient for Th17 polarization. This is consistent with a “two
hit” hypothesis, although in this case, the two hits are H. muridarum and an irritant
rather than host genetics and the microbiome.

I3C shifts the immune balance
The use of alternative medicine to treat inflammatory disorders is appealing to many
patients. Numerous studies demonstrate that dietary indoles possess anti-cancer
properties such as anti-oxidant activity, regulation of cell cycle and apoptosis, and
control of endocrine metabolism[78-83]. DIM is sold over the counter as BioResponse
DIM® with claims that it promotes breast health, prostate health, and weight
management. Before such products can be confidently recommended, their
mechanisms of action must be uncovered. In the case of IBD, it is prudent to
investigate the effect of gut microbiota on response to treatment.
Several natural compounds, including I3C, are AhR ligands[84]. AhR is now known
to govern differentiation and function of both T cells and macrophages[85-87]. Several
studies have shown that AhR plays a vital role in regulation of immune responses
specifically promoting the generation of Tregs while suppressing Th17 cells[88,89].
Previous studies have provided convincing proof that Foxp3-positive Treg cells are
essential for gastrointestinal immune homeostasis[90] and that increased Th17
differentiation promotes colitis[50,51]. Consistent with other reports from various disease
models, we found that I3C increases the Treg population and decreases the Th17
population[91-93]. The shift from Th17 to Treg was not inhibited by H. muridarum
infection. Additionally, we found that I3C reduced production of every other proinflammatory cytokine tested, except for IL-22, which was not affected in any
treatment group. Though we did not specifically analyze macrophages, others have
shown that I3C or DIM suppresses IL-6, TNFα, IL-1β, IL-23 and IFNγ[94-96]. Therefore,
I3C most likely inhibits colitis development via effects on both T cells and
macrophages.
In summary, our studies suggest that H. muridarum increases susceptibility to DSSinduced colitis by inducing macrophage-associated cytokines and creating a mucosal
milieu conducive to Th17 polarization. I3C ameliorates colitis via induction of Tregs,
suppression of Th17 cells, and suppression of macrophage-associated proinflammatory cytokines. While no mouse model perfectly replicates human IBD, the
identities of miRNAs altered by H. muridarum and DSS were similar to colitis studies
in both mice and humans, although the direction of change was not always consistent.
I3C is equally effective in the presence and absence of H. muridarum. Further research
is warranted on the roles of EHH species in human IBD and the use of I3C or similar
AhR agonists for the treatment of inflammatory bowel disease.

ARTICLE HIGHLIGHTS
Research background
Enterohepatic Helicobacter (EHH) species can infect humans and many animal species.
Some of these species are known to cause disease in animals, while others have been
described as commensal. In humans, epidemiological evidence suggests that EHH
species are associated with inflammatory bowel disease (IBD), but the specific species
involved and mechanisms of action are unknown. New treatments being tested for
IBD include natural compounds and microRNA (miRNA)-based therapies. MiRNA is
also being investigated as a diagnostic tool.
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Research motivation
Given the limitations of performing IBD research in humans, an animal model of
EHH-mediated pathology is needed. Such a model should reflect the biological
changes seen during human IBD. Helicobacter muridarum (H. muridarum) has been
referred to as a commensal in mice, yet we previously determined that H. muridarum
worsens colitis resulting from dextran sodium sulfate (DSS). This suggested that EHH
species could represent environmental factors that cause or worsen IBD in genetically
susceptible individuals. It is also important to determine whether phytochemicals
being investigated as IBD treatments are influenced by infection with EHH species
because there are no commercially available tests for EHH infection in humans.

Research objectives
We sought to determine how the immune and miRNA profiles of H. muridaruminfected wild-type mice compared with DSS-treated mice and with published immune
and miRNA profiles of IBD patients. We also determined whether efficacy of a
broccoli-derived anti-inflammatory compound, indole-3-carbinol (I3C), was reduced
by H. muridarum infection.

Research methods
We measured changes in body weight, stool consistency, and stool blood following H.
muridarum infection, DSS treatment, and/or I3C treatment. We then measured
cytokine responses in the colon and plasma and histopathological changes in the
colon. MiRNA changes and T cell population changes were measured in mesenteric
lymph nodes.

Research results
While H. muridarum infection alone did not cause clinical symptoms, it did cause
colonic inflammation and induced proinflammatory cytokines. As expected, H.
muridarum worsened colitis caused by DSS treatment, but it did not prevent
amelioration of colitis by I3C treatment. Both the miRNA changes and cytokine
responses to H. muridarum infection were similar to those seen in human IBD and due
to DSS treatment. Changes in cytokines and miRNA were consistent with a Th17
response.

Research conclusions
H. muridarum causes subclinical colitis that increases vulnerability to DSS treatment.
Since I3C is an aryl hydrocarbon receptor agonist, the efficacy of I3C in the presence of
H. muridarum suggests that H. muridarum does not influence the aryl hydrocarbon
receptor agonist pathway. The strong similarities between cytokine and miRNA
profiles induced by DSS and those induced by H. muridarum suggest that similar
mechanisms could be at play and that the mouse model is suitable for studying host
interactions with EHH species.

Research perspectives
This research supports the hypothesis that EHH species could contribute to human
IBD by exacerbating the response to other inflammatory stimuli. More research is
needed on the prevalence of EHH species in humans and the mechanisms underlying
EHH-mediated colonic damage.
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